Cart
sales@molnova.com
BT2
CAS No. 34576-94-8
BT2( —— )
Catalog No. M22491 CAS No. 34576-94-8
BT2 is a BCKDC kinase (BDK) inhibitor with an IC50 of 3.19 μM. BT2 (compound 4) is also a potent and selective Mcl-1 inhibitor with a Ki value of 59 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 10MG | 37 | In Stock |
|
| 25MG | 55 | In Stock |
|
| 50MG | 67 | In Stock |
|
| 100MG | 98 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 238 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBT2
-
NoteResearch use only, not for human use.
-
Brief DescriptionBT2 is a BCKDC kinase (BDK) inhibitor with an IC50 of 3.19 μM. BT2 (compound 4) is also a potent and selective Mcl-1 inhibitor with a Ki value of 59 μM.
-
DescriptionBT2 is a BCKDC kinase (BDK) inhibitor with an IC50 of 3.19 μM. BT2 (compound 4) is also a potent and selective Mcl-1 inhibitor with a Ki value of 59 μM. BT2 binding to BDK triggers helix movements in the N-terminal domain, resulting in the dissociation of BDK from the branched-chain α-ketoacid dehydrogenase complex (BCKDC).BT2 treatment reduces the protein levels of BDK in kidneys and heart[1]. The -fold activation of BCKDC activity in the above tissues correlates with decreased phosphorylation in heart, muscle, and kidney after the long term BT2 treatment. BT2 (20 mg/kg/day; intraperitoneal injection; daily; for 7 days; C57BL/6J male mice) treatment robustly enhances BCKDC activity in the heart (12.3-fold) compared with the vehicle-treated animals. Less activation is obtained in muscle and kidney at 3.6- and 3.8-fold, respectively.
-
In Vitro——
-
In VivoBT2 (20 mg/kg/day; intraperitoneal injection; daily; for 7 days; C57BL/6J male mice) treatment robustly enhances BCKDC activity in the heart (12.3-fold) compared with the vehicle-treated animals. Less activation is obtained in muscle and kidney at 3.6- and 3.8-fold, respectively. The -fold activation of BCKDC activity in the above tissues correlates with decreased phosphorylation in heart, muscle, and kidney after the long term BT2 treatment. BT2 treatment reduces the protein levels of BDK in kidneys and heart. Animal Model:C57BL/6J male mice (8-10-week-old) Dosage:20 mg/kg/day Administration:Intraperitoneal injection; daily; for 1 week Result:BCKDC activity was robustly (12.3-fold) enhanced in the heart compared with the vehicle-treated animals. Less activation was obtained in muscle and kidney at 3.6- and 3.8-fold, respectively. The protein levels of BDK in kidneys and heart were reduced to averages of 39 and 24%, respectively.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetBcl-2
-
RecptorBDK|Mcl-1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number34576-94-8
-
Formula Weight247.1
-
Molecular FormulaC9H4Cl2O2S
-
Purity>98% (HPLC)
-
SolubilityDMSO:83.33 mg/mL (337.23 mM; Need ultrasonic)
-
SMILESOC(=O)c1sc2cc(Cl)ccc2c1Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Tso SC, et al. Benzothiophene carboxylate derivatives as novel allosteric inhibitors of branched-chain α-ketoacid dehydrogenase kinase. J Biol Chem. 2014 Jul 25;289(30):20583-93.
molnova catalog
related products
-
AZD 4320
AZD4320 is a BH3 mimetic and dual Bcl-2/Bcl-XL inhibitor with IC50 of <1 nM.
-
BAI1
BAI1 (Bax channel blocker) is a potent inhibitor of Bax-mediated mitochondrial cytochrome C release (IC50: 0.52 μM).
-
A09-003
A09-003 is a novel cell cycle protein-dependent kinase-9 CDK-9 inhibitor.A09-003 inhibits the proliferation of a variety of leukemia cell lines and inhibits the increase of leukemia sequence-1 protein in myeloid cells.
